S3-Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM) zu Definition, Pathophysiologie, Diagnostik und Therapie intestinaler Motilitätsstörungen[1]

Inhaltsverzeichnis Abkürzungsverzeichnis 374 Einführung und Methodik 374 Hintergrund und Ziele 374 Methodik 375 Auswahl der Leitlinien-Mitglieder und Struktur der Leitlinie 375 Literatursuche 376 Evidenzgrad und Empfehlungsstärke 377 Definitionen, Pathophysiologie und Histopathologie 378 Enterische Neuropathien 378 Enterische Myopathien 379 Enterische Neuro-Gliopathien und Mesenchymopathien 379 (Differenzial-)Diagnostik 381 Therapie 386

Abkürzungsverzeichnis ACPO akute kolonische Pseudoobstruktion, syn. Ogilvie-Syndrom CED chronisch entzündliche Darmerkrankung CIPO chronische intestinale Pseudoobstruktion CMV Cytomegalie-Virus EBV Ebstein-Barr-Virus EGC enterische Glia-Zellen (engl. cells) ENS enterisches Nervensystem GIT Gastrointestinaltrakt ICC interstitielle Cajal-Zellen (engl. cells) IMC idiopathisches Megakolon/-rektum NTC normal transit constipation, engl. STC slow transit constipation, engl.

1 Für die Konsensusgruppe, Konsensuskonferenz 18./19.9.2009.

Literatur

• 1 Layer P. S3-Leitlinie der DGVS und DGNM zur Definition, Pathophysiologie, Diagnostik und Therapie des Reizdarmsyndroms.  zur Einreichung bei Z Gastroenterol.
• 2 Fachgesellschaften ÄZQAdWM ed. Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI) – Fassung 2005 / 2006 + Domäne 8. Berlin; 2008
• 3 Phillips B, Ball C, Sackett D et al. Oxford-Centre for Evidence-Based Medicine – Levels of Evidence and Grades of Recommendation. 2001
• 4 Kunz R, Burnand B, Schunemann H J. Das GRADE System.  Internist. 2008;  49 673-680
• 5 Connor F L, Di Lorenzo C. Chronic intestinal pseudo-obstruction: assessment and management.  Gastroenterology. 2006;  130 S29-S36
• 6 Stanghellini V, Cogliandro R F, Giorgio de R et al. Chronic intestinal pseudo-obstruction: manifestations, natural history and management.  Neurogastroenterol Motil. 2007;  19 440-452
• 7 Seidl H, Pehl C, Schepp W et al. Chronische intestinale Pseudoobstruktion-Übersicht und Update 2008.  Z Gastroenterol. 2008;  46 704-711
• 8 Kessmann J. Hirschsprung’s disease: diagnosis and management.  Am Fam Physician. 2006;  74 1319-1322
• 9 Furness J B. The enteric nervous system: normal functions and enteric neuropathies.  Neurogastroenterol Motil. 2008;  20 (Suppl 1) 32-38
• 10 Knowles C H, De Giorgio R, Kapur R P et al. The London Classification of gastrointestinal neuromuscular pathology: report on behalf of the Gastro 2009 International Working Group.  Gut. 2010;  59 882-887
• 11 Goyal R K, Hirano I. The enteric nervous system.  N Engl J Med. 1996;  334 1106-1115
• 12 Collins S M. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders.  Gastroenterology. 1996;  111 1683-1699
• 13 Wood J D. Intrinsic neural control of intestinal motility.  Annu Rev Physiol. 1981;  43 33-51
• 14 De Giorgio R, Camilleri M. Human enteric neuropathies: morphology and molecular pathology.  Neurogastroenterol Motil. 2004;  16 515-531
• 15 Di Lorenzo C. Pseudo-obstruction: current approaches.  Gastroenterology. 1999;  116 980-987
• 16 De Giorgio R, Guerrini S, Barbara G et al. New insights into human enteric neuropathies.  Neurogastroenterol Motil. 2004;  16 (Suppl 1) 143-147
• 17 De Giorgio R, Seri M, Cogliandro R et al. Analysis of candidate genes for intrinsic neuropathy in a family with chronic idiopathic intestinal pseudo-obstruction.  Clin Genet. 2001;  59 131-133
• 18 Deglincerti A, De Giorgio R, Cefle K et al. A novel locus for syndromic chronic idiopathic intestinal pseudo-obstruction maps to chromosome 8q23-q24.  Eur J Hum Genet. 2007;  15 889-897
• 19 Gargiulo A, Auricchio R, Barone M V et al. Filamin A is mutated in X-linked chronic idiopathic intestinal pseudo-obstruction with central nervous system involvement.  Am J Hum Genet. 2007;  80 751-758
• 20 Finsterer J. Overview on visceral manifestations of mitochondrial disorders.  Neth J Med. 2006;  64 61-71
• 21 Heanue T A, Pachnis V. Enteric nervous system development and Hirschsprung’s disease: advances in genetic and stem cell studies.  Nat Rev Neurosci. 2007;  8 466-479
• 22 De Giorgio R, Guerrini S, Barbara G et al. Inflammatory neuropathies of the enteric nervous system.  Gastroenterology. 2004;  126 1872-1883
• 23 Smith V V, Gregson N, Foggensteiner L et al. Acquired intestinal aganglionosis and circulating autoantibodies without neoplasia or other neural involvement.  Gastroenterology. 1997;  112 1366-1371
• 24 Di Nardo G, Blandizzi C, Volta U et al. Review article: molecular, pathological and therapeutic features of human enteric neuropathies.  Aliment Pharmacol Ther. 2008;  28 25-42
• 25 Knowles C H, De Giorgio R, Kapur R P et al. Gastrointestinal neuromuscular pathology: guidelines for histological techniques and reporting on behalf of the Gastro 2009 International Working Group.  Acta Neuropathol. 2009;  118 271-301
• 26 Koh S, Bradley R F, French S W et al. Congenital visceral myopathy with a predominantly hypertrophic pattern treated by multivisceral transplantation.  Hum Pathol. 2008;  39 970-974
• 27 Dewit S, Hertogh de G, Geboes K et al. Chronic intestinal pseudo-obstruction caused by an intestinal inflammatory myopathy: case report and review of the literature.  Neurogastroenterol Motil. 2008;  20 343-348
• 28 Bassotti G, Villanacci V, Fisogni S et al. Enteric glial cells and their role in gastrointestinal motor abnormalities: introducing the neuro-gliopathies.  World J Gastroenterol. 2007;  13 4035-4041
• 29 Ruhl A. Glial cells in the gut.  Neurogastroenterol Motil. 2005;  17 777-790
• 30 Bush T G. Enteric glial cells. An upstream target for induction of necrotizing enterocolitis and Crohn’s disease?.  Bioessays. 2002;  24 130-140
• 31 Savidge T C, Sofroniew M V, Neunlist M. Starring roles for astroglia in barrier pathologies of gut and brain.  Lab Invest. 2007;  87 731-736
• 32 Bassotti G, Villanacci V, Maurer C A et al. The role of glial cells and apoptosis of enteric neurones in the neuropathology of intractable slow transit constipation.  Gut. 2006;  55 41-46
• 33 Bassotti G, Villanacci V, Cathomas G et al. Enteric neuropathology of the terminal ileum in patients with intractable slow-transit constipation.  Hum Pathol. 2006;  37 1252-1258
• 34 Bassotti G, Villanacci V, Nascimbeni R et al. Colonic neuropathological aspects in patients with intractable constipation due to obstructed defecation.  Mod Pathol. 2007;  20 367-374
• 35 Dinning P G, Bampton P A, Andre J et al. Abnormal predefecatory colonic motor patterns define constipation in obstructed defecation.  Gastroenterology. 2004;  127 49-56
• 36 Iantorno G, Bassotti G, Kogan Z et al. The enteric nervous system in chagasic and idiopathic megacolon.  Am J Surg Pathol. 2007;  31 460-468
• 37 Cajal. Sur les ganglions et plexus nerveux d’intestin.  C R Soc Biol. 1893;  5 217-223
• 38 Sarna S K. Are interstitial cells of Cajal plurifunction cells in the gut?.  Am J Physiol Gastrointest Liver Physiol. 2008;  294 G372-G390
• 39 Sanders K M, Koh S D, Ward S M. Interstitial cells of cajal as pacemakers in the gastrointestinal tract.  Annu Rev Physiol. 2006;  68 307-343
• 40 Knowles C H, De Giorgio R, Kapur R P et al. Gastrointestinal neuromuscular pathology: guidelines for histological techniques and reporting on behalf of the Gastro 2009 International Working Group.  Acta Neuropathol. 2009;  118 271-301
• 41 Huizinga J D, Lammers W J. Gut peristalsis is governed by a multitude of cooperating mechanisms.  Am J Physiol Gastrointest Liver Physiol. 2009;  296 G1-G8
• 42 Yanagida H, Yanase H, Sanders K M et al. Intestinal surgical resection disrupts electrical rhythmicity, neural responses, and interstitial cell networks.  Gastroenterology. 2004;  127 1748-1759
• 43 De Giorgio R, Sarnelli G, Corinaldesi R et al. Advances in our understanding of the pathology of chronic intestinal pseudo-obstruction.  Gut. 2004;  53 1549-1552
• 44 Smout A J. Recent developments in gastrointestinal motility.  Scand J Gastroenterol Suppl. 2006;  243 25-31
• 45 Stanghellini V, Cogliandro R F, De Giorgio R et al. Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study.  Clin Gastroenterol Hepatol. 2005;  3 449-458
• 46 Eisen G M, Baron T H, Dominitz J A et al. Acute colonic pseudo-obstruction.  Gastrointest Endosc. 2002;  56 789-792
• 47 Saunders M D. Acute colonic pseudo-obstruction.  Gastrointest Endosc Clin N Am. 2007;  17 341-360, vi-vii
• 48 Saunders M D, Kimmey M B. Systematic review: acute colonic pseudo-obstruction.  Aliment Pharmacol Ther. 2005;  22 917-925
• 49 Saunders M D. Acute colonic pseudo-obstruction.  Best Pract Res Clin Gastroenterol. 2007;  21 671-687
• 50 Vanek V W, Al-Salti M. Acute pseudo-obstruction of the colon (Ogilvie’s syndrome). An analysis of 400 cases.  Dis Colon Rectum. 1986;  29 203-210
• 51 Gladman M A, Knowles C H. Novel concepts in the diagnosis, pathophysiology and management of idiopathic megabowel.  Colorectal Dis. 2008;  10 531-538 ; discussion 538 – 540
• 52 Bharucha A E. Constipation.  Best Pract Res Clin Gastroenterol. 2007;  21 709-731
• 53 Martucciello G. Hirschsprung’s disease, one of the most difficult diagnoses in pediatric surgery: a review of the problems from clinical practice to the bench.  Eur J Pediatr Surg. 2008;  18 140-149
• 54 Longstreth G F, Thompson W G, Chey W D et al. Functional bowel disorders.  Gastroenterology. 2006;  130 1480-1491
• 55 Wong S W, Lubowski D Z. Slow-transit constipation: evaluation and treatment.  ANZ J Surg. 2007;  77 320-328
• 56 Bassotti G, Villanacci V. Slow transit constipation: a functional disorder becomes an enteric neuropathy.  World J Gastroenterol. 2006;  12 4609-4613
• 57 Rao S S. Constipation: evaluation and treatment of colonic and anorectal motility disorders.  Gastroenterol Clin North Am. 2007;  36 687-711, x
• 58 Bassotti G, Stanghellini V, Chiarioni G et al. Upper gastrointestinal motor activity in patients with slow-transit constipation. Further evidence for an enteric neuropathy.  Dig Dis Sci. 1996;  41 1999-2005
• 59 Seidl H, Gundling F, Pehl C et al. Small bowel motility in functional chronic constipation.  Neurogastroenterol Motil. 2009;  21 1278-e122
• 60 Glia A, Akerlund J E, Lindberg G. Outcome of colectomy for slow-transit constipation in relation to presence of small-bowel dysmotility.  Dis Colon Rectum. 2004;  47 96-102
• 61 Andromanakos N, Skandalakis P, Troupis T et al. Constipation of anorectal outlet obstruction: pathophysiology, evaluation and management.  J Gastroenterol Hepatol. 2006;  21 638-646
• 62 Ouyang A, Locke 3 rd G R. Overview of neurogastroenterology-gastrointestinal motility and functional GI disorders: classification, prevalence, and epidemiology.  Gastroenterol Clin North Am. 2007;  36 485-498, vii
• 63 Spiller R. Role of motility in chronic diarrhoea.  Neurogastroenterol Motil. 2006;  18 1045-1055
• 64 Camilleri M, Bharucha A E, Lorenzo di C et al. American Neurogastroenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice.  Neurogastroenterol Motil. 2008;  20 1269-1282
• 65 Keller J, Franke A, Storr M et al. Klinisch relevante Atemtests in der gastroenterologischen Diagnostik – Empfehlungen der Deutschen Gesellschaft für Neurogastroenterologie und Motilität sowie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselerkrankungen.  Z Gastroenterol. 2005;  43 1071-1090
• 66 Antonucci A, Fronzoni L, Cogliandro L et al. Chronic intestinal pseudo-obstruction.  World J Gastroenterol. 2008;  14 2953-2961
• 67 Pehl C, Enck P, Franke A et al. Empfehlungen zur anorektalen Manometrie im Erwachsenenalter.  Z Gastroenterol. 2007;  45 397-417
• 68 Camilleri M. New imaging in neurogastroenterology: an overview.  Neurogastroenterol Motil. 2006;  18 805-812
• 69 Lorijn de F, Kremer L C, Reitsma J B et al. Diagnostic tests in Hirschsprung disease: a systematic review.  J Pediatr Gastroenterol Nutr. 2006;  42 496-505
• 70 Rao S S, Ozturk R, Laine L. Clinical utility of diagnostic tests for constipation in adults: a systematic review.  Am J Gastroenterol. 2005;  100 1605-1615
• 71 American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America.  Am J Gastroenterol. 2005;  100 (Suppl 1) S1-S4
• 72 Keller J, Layer P. Intestinal and anorectal motility and functional disorders.  Best Pract Res Clin Gastroenterol. 2009;  23 407-423
• 73 Ponec R J, Saunders M D, Kimmey M B. Neostigmine for the treatment of acute colonic pseudo-obstruction.  N Engl J Med. 1999;  341 137-141
• 74 Camilleri M, Kerstens R, Rykx A et al. A placebo-controlled trial of prucalopride for severe chronic constipation.  N Engl J Med. 2008;  358 2344-2354
• 75 Tack J, Outryve van M, Beyens G et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives.  Gut. 2009;  58 357-365
• 76 Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth.  Chemotherapy. 2005;  51 (Suppl 1) 1-22
• 77 Lloyd D A, Gabe S M. Managing liver dysfunction in parenteral nutrition.  Proc Nutr Soc. 2007;  66 530-538
• 78 Sabate J M, Jouet P, Harnois F et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis.  Obes Surg. 2008;  18 371-377
• 79 Grunkemeier D M, Cassara J E, Dalton C B et al. The narcotic bowel syndrome: clinical features, pathophysiology, and management.  Clin Gastroenterol Hepatol. 2007;  5 1126-1139 ; quiz 1121 – 1122
• 80 Tuteja A K, Biskupiak J, Stoddard G J et al. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain.  Neurogastroenterol Motil. 2010;  22 424-430, e96
• 81 Mehendale S R, Yuan C S. Opioid-induced gastrointestinal dysfunction.  Dig Dis. 2006;  24 105-112
• 82 Panchal S J, Muller-Schwefe P, Wurzelmann J I. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden.  Int J Clin Pract. 2007;  61 1181-1187
• 83 Loftus C G, Harewood G C, Baron T H. Assessment of predictors of response to neostigmine for acute colonic pseudo-obstruction.  Am J Gastroenterol. 2002;  97 3118-3122
• 84 Wald A. Constipation in the primary care setting: current concepts and misconceptions.  Am J Med. 2006;  119 736-739
• 85 Ramkumar D, Rao S S. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review.  Am J Gastroenterol. 2005;  100 936-971
• 86 Brandt L J, Prather C M, Quigley E M et al. Systematic review on the management of chronic constipation in North America.  Am J Gastroenterol. 2005;  100 (Suppl 1) S5-S21
• 87 Quartero A O, Meineche-Schmidt V, Muris J et al. Bulking agents, antispasmodic and antidepressant medication for the treatment of irriable bowel syndrome.  Cochrane Database Syst Rev. 2005;  18 CD003460
• 88 Lederle F A, Busch D L, Mattox K M et al. Cost-effective treatment of constipation in the elderly: a randomized double-blind comparison of sorbitol and lactulose.  Am J Med. 1990;  89 597-601
• 89 Muller-Lissner S A, Kamm M A, Scarpignato C et al. Myths and misconceptions about chronic constipation.  Am J Gastroenterol. 2005;  100 232-242
• 90 Mollenbrink M, Bruckschen E. Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor).  Med Klin. 1994;  89 587-593
• 91 Voderholzer W A, Schatke W, Muhldorfer B E et al. Clinical response to dietary fiber treatment of chronic constipation.  Am J Gastroenterol. 1997;  92 95-98
• 92 Koh C E, Young C J, Young J M et al. Systematic review of randomized controlled trials of the effectiveness of biofeedback for pelvic floor dysfunction.  Br J Surg. 2008;  95 1079-1087
• 93 Enck P, Voort van der I, Klosterhalfen S. Biofeedback therapy in fecal incontence and constipation.  Neurogastroenterol Motil. 2009;  21 1133-1141
• 94 Coran A G, Teitelbaum D H. Recent advances in the management of Hirschsprung’s disease.  Am J Surg. 2000;  180 382-387
• 95 Weidner B C, Waldhausen J H. Swenson revisited: a one-stage, transanal pull-through procedure for Hirschsprung’s disease.  J Pediatr Surg. 2003;  38 1208-1211
• 96 Rintala R J. Transanal coloanal pull-through with a short muscular cuff for classic Hirschsprung’s disease.  Eur J Pediatr Surg. 2003;  13 181-186
• 97 Hadidi A. Transanal endorectal pull-through for Hirschsprung’s disease: a comparison with the open technique.  Eur J Pediatr Surg. 2003;  13 176-180
• 98 Langer J C, Durrant A C, Torre de la L et al. One-stage transanal Soave pullthrough for Hirschsprung disease: a multicenter experience with 141 children.  Ann Surg. 2003;  238 569-583 ; discussion 583 – 585
• 99 Tomita R, Ikeda T, Fujisaki S et al. Hirschsprung’s disease and its allied disorders in adults’ histological and clinical studies.  Hepatogastroenterology. 2003;  50 1050-1053
• 100 Hadidi A. Transanal endorectal pull-through for Hirschsprung’s disease: experience with 68 patients.  J Pediatr Surg. 2003;  38 1337-1340
• 101 Saleh W, Rasheed K, Mohaidly M A et al. Management of Hirschsprung’s disease: a comparison of Soave’s and Duhamel’s pull-through methods.  Pediatr Surg Int. 2004;  20 590-593
• 102 Hyman P E. Adolescents and young adults with Hirschsprung’s disease.  Curr Gastroenterol Rep. 2006;  8 425-429
• 103 Miyamoto M, Egami K, Maeda S et al. Hirschsprung’s disease in adults: report of a case and review of the literature.  J Nippon Med Sch. 2005;  72 113-120
• 104 Nyam D C, Pemberton J H, Ilstrup D M et al. Long-term results of surgery for chronic constipation.  Dis Colon Rectum. 1997;  40 273-279
• 105 Kamm M A, Hawley P R, Lennard-Jones J E. Outcome of colectomy for severe idiopathic constipation.  Gut. 1988;  29 969-973
• 106 Ripetti V, Caputo D, Greco S et al. Is total colectomy the right choice in intractable slow-transit constipation?.  Surgery. 2006;  140 435-440

1 Für die Konsensusgruppe, Konsensuskonferenz 18./19.9.2009.

12 ² Mittlerweile ist in Deutschland das Prokinetikum Prucaloprid zur Therapie der Obstipation bei Frauen, bei denen Laxantien nicht ausreichend wirken, zugelassen (vgl. Kommentar zu Statement 8) und kann auch bei STC angewandt werden. Die Zulassung fiel aber in den Zeitraum nach Abschluss der Leitlinienstatements. Die Empfehlung, Prucaloprid bei auf Laxantien unzureichend ansprechender Obstipation zumindest probatorisch zu geben, wurde aus diesem formalen Grund nicht in das Statement aufgenommen.